Back
Adaptimmune Therapeutics PLC 10K Form
Sell
22
ADAP
Adaptimmune Therapeutics PLC
Last Price:
0.87
Seasonality Move:
-9.46%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2023-08-09 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2023-05-12 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2022-11-08 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2022-08-04 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
| 2022-05-09 | 10Q | ADAP/Adaptimmune Therapeutics PLC Quarterly |
Receive ADAP News And Ratings
See the #1 stock for the next 7 days that we like better than ADAP
ADAP Financial Statistics
Sales & Book Value
| Annual Sales: | $60.28M |
|---|---|
| Cash Flow: | $-32.31M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.10 |
| Price / Book: | 9.23 |
Profitability
| EPS (TTM): | -0.66000 |
|---|---|
| Net Income (TTM): | $-163.41M |
| Gross Margin: | $192.68M |
| Return on Equity: | -225.37% |
| Return on Assets: | -55.65% |
Adaptimmune Therapeutics PLC Earnings Forecast
Key Adaptimmune Therapeutics PLC Financial Ratios
- The Gross Profit Margin over the past 7 years for ADAP is 709.74%.
- The Selling, General & Administrative Expenses for ADAP have been equal to 119.13% of Gross Profit Margin.
- The Research & Development expenses have been 209.87% of Revenue.
- The Interest Expense is -1.52% of Operating Income.
- The Net Earning history of ADAP is -188.90% of Total Revenues.
- Per Share Earnings over the last 11 years have been positive in 3 years.
Adaptimmune Therapeutics PLC Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ADAP |
| CUSIP: | 00653A |
| Website: | adaptimmune.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 2.81 |
| Quick Ratio: | 2.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ADAP Technical Analysis vs Fundamental Analysis
Sell
22
Adaptimmune Therapeutics PLC (ADAP)
is a Sell
Is Adaptimmune Therapeutics PLC a Buy or a Sell?
-
Adaptimmune Therapeutics PLC stock is rated a Sell
The current Adaptimmune Therapeutics PLC [ADAP] share price is $0.88. The Score for ADAP is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.